Study ties survival to inflammatory markers in breast cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 7
Volume 18
Issue 7

Two proteins could become important prognostic markers for long-term survival in breast cancer patients, according to researchers at Seattle’s Fred Hutchinson Cancer Research Center.

Two proteins could become important prognostic markers for long-term survival in breast cancer patients, according to researchers at Seattle’s Fred Hutchinson Cancer Research Center.

The proteins, C-reactive protein (CRP) and serum amyloid A (SAA), are associated with chronic inflammation, known to contribute to cancer development and progression. Cornelia Ulrich, PhD, and colleagues measured the levels of CRP and SAA in 734 breast cancer patients at 31 months after diagnosis. They found elevated levels of CRP and SAA are associated with reduced overall breast cancer survival, regardless of patient age, tumor stage, race, and body mass index (J Clin Oncol online, May 26, 2009).

Women in the highest third of SAA levels were three times more likely to die from breast cancer within seven years than patients in the lowest third. Women in the highest third of CRP levels had a twofold increased risk of death.

Recent Videos
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content